Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$17.85 - $40.7 $5.36 Million - $12.2 Million
300,000 New
300,000 $5.81 Million
Q3 2021

Nov 15, 2021

SELL
$46.0 - $73.99 $1.61 Million - $2.59 Million
-35,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$31.92 - $60.25 $1.12 Million - $2.11 Million
35,000 New
35,000 $2.11 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $291M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.